EX-99 2 exhibit_1.htm PRESS RELEASE
Exhibit 1

 
For Immediate Release

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
and Portfolio Updates

- Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in
stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target
action date of September 9, 2023 -

-  Introduced plan to commercialize APHEXDA® independently in the U.S., if approved, and
named Holly May, President, BioLineRx USA  -

- Completed $40M debt financing agreement and $15M equity offering to support aggressive
commercial U.S. launch of APHEXDA®

- Management to hold conference call today, November 15, at 10:00 am EST -

TEL AVIV, Israel, November 15, 2022 – (PRNewswire) – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.

“The Company delivered outstanding performance during the third quarter and subsequent period.  Last week’s FDA acceptance of our new drug application for APHEXDA® (motixafortide) substantially advances our twin goals of delivering an important new therapy for the mobilization of stem cells in preparation for autologous transplantation in patients with multiple myeloma, and in parallel, transitioning to a commercial stage company,” said Philip Serlin, Chief Executive Officer of BioLineRx.  “Importantly, we took steps that allow us to rapidly commercialize APHEXDA®, if approved, including securing financing, building out our U.S. operations, and progressing our launch strategy.  We believe that APHEXDA® has the potential to become the standard-of-care mobilizing agent for multiple myeloma patients.”

“Additionally, working with our collaborators, we advanced motixafortide development programs for pancreatic cancer, reflecting motixafortide’s potential broad clinical utility.  Finally, we anticipate sharing data from the Phase 1/2a trial of our solid tumor investigational immunotherapy AGI-134 prior to year-end.  We believe we are well-positioned to execute across all of our programs and continue to aggressively plan for the potential launch of APHEXDA® next year,” Mr. Serlin concluded.


Recent Corporate Updates


 •
Completed $40 million non-dilutive debt financing agreement with Kreos Capital and $15 million registered direct offering to support commercial launch of APHEXDA® in the U.S.

•
Announced APHEXDA® U.S. commercialization plan and named Holly May, President, BioLineRx USA

Portfolio Execution

Motixafortide (selective inhibitor of CXCR4 chemokine receptor)

Multiple Myeloma

 •
Announced FDA acceptance of APHEXDA® NDA in stem cell mobilization for autologous transplantation in multiple myeloma patients. PDUFA target action date set for September 9, 2023

•
Announced presentation of cost-effectiveness analysis of motixafortide versus plerixafor in stem cell mobilization for autologous transplantation in patients with multiple myeloma at the American Society of Hematology (ASH) 64th Annual Meeting, which is being held December 10-13, 2022, in New Orleans, Louisiana

Pancreatic Ductal Adenocarcinoma (PDAC)

 •
Began Phase 2b PDAC randomized clinical trial preparation activities with collaboration partner GenFleet.  Anticipate clinical trial initiation in 2023.  The collaboration agreement allows BioLineRx to retain global rights to motixafortide in all indications

•
Continued collaboration progress in Columbia University investigator-initiated Phase 2 study of motixafortide in combination with an anti-PD-1 and standard-of-care chemotherapy in first-line PDAC patients

Sickle Cell Disease & Gene Therapy

 •
Announced presentation of clinical trial study design of novel stem cell mobilization regimen with motixafortide to support gene therapy development for sickle cell patients at the ASH Annual Meeting, which is being held December 10-13, 2022, in New Orleans, Louisiana

AGI-134 (synthetic alpha-Gal glycolipid)

Solid Tumor Immunotherapy

 •
Advanced biomarker analysis from the Phase 1/2a trial of AGI-134 in solid tumors and anticipate announcing results from Part 2 of the trial by year-end

Third Quarter 2022 Financial Results
 

 •
Research and development expenses for the quarter ended September 30, 2022, were $4.4 million compared to $4.9 million for the same period in 2021; the decrease resulted primarily from lower expenses related to motixafortide NDA supporting activities, as well as lower expenses associated with the completed motixafortide GENESIS clinical trial, offset by an increase in payroll and related expenses

•
Sales and marketing expenses for the quarter ended September 30, 2022, were $1.3 million compared to $0.2 million for the same period in 2021; the increase resulted primarily from initiation of pre-commercialization activities related to motixafortide, as well as an increase in market research

•
General and administrative expenses for the quarter ended September 30, 2022, were $1.4 million compared to $1.0 million for the same period in 2021; the increase resulted primarily from an increase in share-based compensation and small increases across several G&A expenses

•
Net loss for the quarter ended September 30, 2022, was $6.8 million, compared to $5.7 million for the same period in 2021

•
As of September 30, 2022, the Company had cash, cash equivalents, and short-term bank deposits of $57.3 million and anticipates this will be sufficient to fund operations, as currently planned, into the first half of 2024

Conference Call and Webcast Information
BioLineRx will hold a conference call today, Tuesday, November 15 at 10:00 a.m. EST. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until November 17, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5903 internationally.

About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.  APHEXDA® (motixafortide) was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation in multiple myeloma patients, has reported positive results from a pre-planned pharmacoeconomic study in the U.S., and has had its NDA submission accepted by the FDA with a PDUFA date of September 9, 2023. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer (PDAC) in combination with KEYTRUDA® and chemotherapy and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy. A randomized phase 2b study with 200 patients in combination with PD1 and chemotherapy as a first-line PDAC therapy will initiate in 2023. BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study. For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.

Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 16, 2022. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

United States

John Lacey
BioLineRx
+1-781-392-5514
johnl@biolinerx.com

Israel

Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com


BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)

   
Three months ended
September 30,
    
Nine months ended
September 30,
  
   
2021
    
2022
    
2021
    
2022
  
   
in USD thousands
    
in USD thousands
  
RESEARCH AND DEVELOPMENT EXPENSES
    
(4,923
)
    
(4,369
)
    
(14,340
)
    
(14,199
)
SALES AND MARKETING EXPENSES
    
(247
)
    
(1,317
)
    
(731
)
    
(3,112
)
GENERAL AND ADMINISTRATIVE EXPENSES
    
(1,047
)
    
(1,392
)
    
(3,108
)
    
(3,448
)
OPERATING LOSS
    
(6,217
)
    
(7,078
)
    
(18,179
)
    
(20,759
)
NON-OPERATING INCOME (EXPENSES), NET
    
710
      
389
      
(4,068
)
    
2,115
  
FINANCIAL INCOME
    
52
      
109
      
299
      
256
  
FINANCIAL EXPENSES
    
(261
)
    
(267
)
    
(802
)
    
(832
)
                                 
NET LOSS AND COMPREHENSIVE LOSS
    
(5,716
)
    
(6,847
)
    
(22,750
)
    
(19,220
)
                                 
   
in USD
    
in USD
  
LOSS PER ORDINARY SHARE - BASIC AND DILUTED
    
(0.01
)
    
(0.01
)
    
(0.04
)
    
(0.03
)
                                 
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE
    
708,473,164
      
740,767,492
      
646,427,790
      
723,805,390
  


BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)

   
December 31,
    
September 30,
  
   
2021
    
2022
  
   
in USD thousands
  
Assets
            
CURRENT ASSETS
            
Cash and cash equivalents
    
12,990
      
13,105
  
Short-term bank deposits
    
44,145
      
44,157
  
Prepaid expenses
    
127
      
537
  
Other receivables
    
142
      
143
  
Total current assets
    
57,404
      
57,942
  
                 
NON-CURRENT ASSETS
                
Property and equipment, net
    
952
      
726
  
Right-of-use assets, net
    
1,331
      
1,289
  
Intangible assets, net
    
21,704
      
21,716
  
Total non-current assets
    
23,987
      
23,731
  
Total assets
    
81,391
      
81,673
  
                 
Liabilities and equity
                
CURRENT LIABILITIES
                
Current maturities of long-term loan
    
2,757
      
802
  
Accounts payable and accruals:
                
Trade
    
5,567
      
5,829
  
Other
    
1,227
      
1,351
  
Current maturities of lease liabilities
    
168
      
151
  
Total current liabilities
    
9,719
      
8,133
  
NON-CURRENT LIABILITIES
                
Warrants
    
1,859
      
8,156
  
Long-term loan, net of current maturities
    
-
      
8,353
  
Lease liabilities
    
1,726
      
1,507
  
Total non-current liabilities
    
3,585
      
18,016
  
COMMITMENTS AND CONTINGENT LIABILITIES
                
Total liabilities
    
13,304
      
26,149
  
                 
EQUITY
                
Ordinary shares
    
21,066
      
27,098
  
Share premium
    
339,346
      
338,841
  
Warrants
    
975
      
1,408
  
Capital reserve
    
13,157
      
13,854
  
Other comprehensive loss
    
(1,416
)
    
(1,416
)
Accumulated deficit
    
(305,041
)
    
(324,261
)
Total equity
    
68,087
      
55,524
  
Total liabilities and equity
    
81,391
      
81,673